Strategy Asset Managers’s Regeneron Pharmaceuticals REGN Stock Holding History

Strategy Asset Managers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-441	Closed	-$314K	–	263
2024 Q4	$314K	Sell	441 -107	-20%	-$89.8K	0.06%	198
2024 Q3	$576K	Buy	+548	New	+$610K	0.11%	139
2024 Q1	–	Sell	-678	Closed	-$595K	–	253
2023 Q4	$595K	Sell	678 -89	-12%	-$73.3K	0.14%	108
2023 Q3	$631K	Buy	+767	New	+$603K	0.17%	102
2021 Q1	–	Sell	-988	Closed	-$477K	–	275
2020 Q4	$477K	Sell	988 -447	-31%	-$241K	0.11%	140
2020 Q3	$803K	Buy	1,435 +1,042	+265%	+$632K	0.21%	89
2020 Q2	$245K	Buy	+393	New	+$223K	0.07%	199
2019 Q2	–	Sell	-42	Closed	-$17K	–	181
2019 Q1	$17K	Buy	+42	New	+$17.3K	﹤0.01%	182
2018 Q4	–	Sell	-1,092	Closed	-$441K	–	130
2018 Q3	$441K	Hold	1,092	–	–	0.09%	114
2018 Q2	$377K	Buy	+1,092	New	+$342K	0.08%	114
2018 Q1	–	Sell	-1,092	Closed	-$411K	–	137
2017 Q4	$411K	Buy	+1,092	New	+$442K	0.08%	115
2016 Q3	–	Sell	-6,187	Closed	-$2.16M	–	141
2016 Q2	$2.16M	Sell	6,187 -44	-0.7%	-$16.9K	0.49%	72
2016 Q1	$2.25M	Buy	6,231 +220	+4%	+$90.7K	0.51%	72
2015 Q4	$3.26M	Buy	6,011 +45	+0.8%	+$24.4K	0.74%	38
2015 Q3	$2.77M	Hold	5,966	–	–	0.67%	43
2015 Q2	$3.04M	Sell	5,966 -12	-0.2%	-$5.86K	0.68%	43
2015 Q1	$2.7M	Buy	+5,978	New	+$2.53M	0.59%	56

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Strategy Asset Managers's REGN Position: Q1 2025 in Review

Strategy Asset Managers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 441 shares — an estimated $314K sold.

Strategy Asset Managers first reported a position in REGN in Q1 2015 and held it in 17 quarters. The position peaked at $3.26M in Q4 2015. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Strategy Asset Managers reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Strategy Asset Managers sold 441 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $314K.
Strategy Asset Managers first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 17 quarters.
Strategy Asset Managers's Regeneron Pharmaceuticals position peaked at $3.26M in Q4 2015.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Strategy Asset Managers's 13F filing for Q1 2025, filed 9 May 2025.